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1. Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common type of 
malignancy worldwide, and represents over 6% of the global cancer burden 1. Each year, 
HNSCC accounts for nearly 650,000 new cases of cancer, and over 35,000 deaths worldwide 
1, 2. Historically, HNSCC has been a challenging disease to manage, with locally advanced 
disease often requiring a multidisciplinary approach of surgery, chemotherapy and 
radiation. However, despite significant advances among the aforementioned fields, the 
current 5-year survival rate of approximately 50% has improved very little over the last 30 
years 2, 3. This poor improvement in prognosis is a reflection of the unique treatment 
challenges presented by HNSCC, which include advanced stages at diagnosis, high 
recurrence rate after surgical removal and second primary tumor development 4. Moreover, 
not only are current treatment options often non-curative, but they are associated with 
significant morbidity, including substantial physical deformity and functional deficits. 
Together, these challenges underscore the importance of developing novel anti-neoplastic 
treatment strategies which may improve survival and quality of life among HNSCC 
patients. 
One of the more intriguing novel anti-neoplastic agents is 1,25-dihydroxyvitamin D3 
[(1,25(OH)2D3), calcitriol], the hormone first identified as an effective treatment for rickets, 
which has recently garnered wide-spread support as a possible anti-neoplastic agent in a 
number of different cancer subtypes 5. Epidemiological observational studies, performed 
mainly in the United States, have long postulated a correlation between higher latitude 
residence and overall cancer incidence and mortality. The first such theory was put forth in 
1937 by Peller and Stephenson, who together hypothesized that increased sunlight exposure 
lowered the risk of cancer 6. Four years later, observational studies defined the relationship 
further, demonstrating a significant association between geographic latitude and cancer 
mortality 7. Since that time, scientists have continued to hypothesize that inadequate serum 
vitamin D levels at higher latitudes increases one’s risk for a number of different cancers 
including colon, breast, prostate and ovarian cancers 8-11. Large cohort studies have 
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confirmed similar findings among HNSCC patients as well. Such studies have not only 
demonstrated significantly reduced 25-hydroxyvitamin D [25(OH)D] serum levels among 
HNSCC patients, but also found disease-free survival time to be significantly associated 
with 25(OH)D serum levels 12. 
However, a definitive causal relationship is perhaps not as clear as it seems. Though these 
reports have evoked widespread enthusiasm within the scientific community, such zeal has 
remained tempered. Most of the data regarding an association between 25(OH)D and cancer 
is derived from retrospective ecological observational studies. To date, no large-scale 
randomized control trials have ever been done examining serum 25(OH)D levels and a 
primary outcome of cancer. In fact, smaller randomized control studies are extremely 
limited and yield conflicting results as to the significance of this relationship 13. There are 
several prospective studies examining the relationship, but such studies have offered no 
consensus findings regarding the association 14, 15. 
The continued optimism regarding vitamin D’s role as an anti-neoplastic agent is sustained, 
however, by a number of molecular studies which support the biologic feasibility of the 
theory. In particular, proponents cite the widely expressed vitamin D receptor (VDR), which 
to date has been found in over 30 different human tissues including lymphocytes, muscle, 
skin and cancer cells 16, 17. Furthermore, the terminal enzyme in the synthesis of active 
Vitamin D, 1--hydroxylase, also exhibits widespread expression allowing for synthesis of 
the hormonally active metabolite in a number of different cell types. Not only is vitamin D 
capable of ubiquitous synthesis and action, but in vivo studies within both human and 
animal models suggest that the active metabolite of vitamin D (calcitriol) is capable of 
eliciting a number of non-calcemic downstream effects. Many of these actions can be 
considered anti-neoplastic in nature, including anti-inflammatory, proapoptotic, and 
antiangiogenic properties, the promotion of cell differentiation, and the inhibition of cancer-
cell proliferation.  
In this chapter we describe the relevant molecular and biological mechanisms regarding 
Vitamin D metabolism. We also describe the basic and inherent anti-cancerous properties of 
vitamin D metabolites, with a specific emphasis on its role in the management of HNSCC. 
2. Overview of vitamin D biological activity 
In 1919, Sir Edward Mellanby conducted a series of elegantly designed experiments on 
rachitic canines. By placing strict restrictions on both diet and sunlight exposure, he was 
able to establish a causal relationship between the bone disease rickets and a deficiency of 
an unidentified trace dietary substance. Mellanby concluded, at that time, that the unknown 
entity was most likely a previously undescribed fat-soluble vitamin. It was not until 1932, 
however, that Vitamin D’s chemical structure was formally characterized, revealing that 
Vitamin D was not actually a vitamin, but a steroid hormone. In the late 1960s it was 
discovered that vitamin D was actually a precursor of a new steroid hormone, 1,25(OH)2D3, 
produced intrarenally. As both the physical structure and physiologic actions of 
1,25(OH)2D3 continued to be better characterized, it was soon found to be a critical 
component of both calcium homeostasis and overall bone health. As research progressed 
into the 21st century, scientists discovered that the hormone impacted a number of 
important non-calcemic cell regulatory functions. 
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Today, what is commonly referred to as “Vitamin D” is actually a combination of 
ergocalciferol (vitamin D2) and cholicalciferol (vitamin D3). Both compounds are readily 
available in diet form, with vitamin D2 being found in plant products and vitamin D3 found 
predominately in fatty fish, fish liver oil, and eggs with smaller amounts found in cheese 
and meat products. In either case, the total amount of either vitamin found within food 
items is relatively small; thus, many developed countries, including the United States, have 
turned to fortifying numerous food items, such as milk and juices, with both vitamin D2 and 
vitamin D3. Despite food fortification, diet is not the body’s primary means for acquiring 
vitamin D3 stores. Instead, the majority of the body’s cholecalciferol is synthesized in vivo 
through a photosynthic process occurring in the epidermal layer of sun-exposed skin. Upon 
exposure to ultraviolet radiation, the epidermis is capable of transforming a cholesterol 
derivative (7-dehydrocholesterol) into vitamin D3 (cholecalciferol). The catalysis, however, is 
not uniform among all populations and is subject to significant and intense variations based 
on skin pigmentation, sunscreen use, age, gender and even obesity 18.  
After synthesis, cholecalciferol enters the blood stream and is transported to the liver. There 
it undergoes intra-hepatic hydroxylation at the 25 position to create 25-hydroxyvitamin D3 
[25(OH)D3 or calcidiol]. 25(OH)D3 is the circulating form of the hormone within the plasma 
as well as the most accurate biomarker of overall Vitamin D3 status 19. 25(OH)D3 is next 
catalyzed into one of two metabolites: the biologically inert 24,25-dihydroxyvitamin D3 
[24,25(OH)2D3] or the biologically active metabolite 1,25-dihydroxyvitamin D3 
[1,25(OH)2D3]. Exactly which metabolite is created depends entirely on what enzyme is 
expressed within the local tissue. If the tissue expresses 24-hydroxylase (also known as 
CYP24A1), then 25(OH)D3 is modified to become 24,25(OH)2D3. This particular metabolite 
has poor affinity and avidity toward the VDR and is considered the first step in vitamin D 
decomposition. Alternatively, if the tissue expresses 1- hydroxylase (also known as 
CYP27B1), the biologically active metabolite 1,25(OH)2D3 is formed. This particular 
metabolite is most well known for its regulation of calcium homeostasis and is the 
metabolite capable of exerting anti-neoplastic effects on cancer cells. 
3. Vitamin D mechanism of action 
The majority of Vitamin D’s hormonal action involves direct interaction with a single VDR. 
An intranuclear regulator of gene transcription, the VDR is a member of the class II steroid 
hormone receptors and is closely related to the retinoic acid and thyroid hormone receptors 
17. The human receptor is located on chromosome 12q12q14 and consists of nine exons. Fully 
transcribed, the receptor is a 427-amino acid peptide with relatively simple binding 
configuration consisting of a DNA-binding domain termed the C-domain, a ligand-binding 
domain called the E-domain and an activating domain called the F-domain. The receptor 
acts by interacting with portions of DNA called vitamin D-responsive elements (VDREs). 
Located in the promoter region of target genes, VDRES are commonly found within 1 
kilobase from the gene start sequence. Such areas are composed of hexanucleotide repeats 
separated by 3 nonspecified nucleotide bases (for example CGACTA-NNN-CGACTA where 
N represents any nucleotide). 
Once 1,25(OH)2D3 is transported into the cell, it enters the nucleus where it is capable of 
binding to VDR. After binding, the 1,25(OH)2D3-VDR complex synergistically 
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heterodimierizes with retinoid-X receptor (RXR). The 1,25(OH)2D3-VDR-RXR complex then 
binds specifically to a VDRE sequence complex, with the VDR occupying the 3’ region and 
the RXR positioned at the 5’ end. Conformational changes which occur after 1,25(OH)2D3 
binding results in the release of coreppressors and the simultaneous exposure of binding 
sites for transcriptional coactivators. VDR coactivators are then capable of binding the 
complex, which results in the acetylation and subsequent release of histones from the DNA 
strand. Without histones in place, the appropriate transcription factors are capable of 
binding to the naked DNA strand and transcription of the target gene is able to initiate. 
Certain variables that construct this transcriptional machinery apparatus may have a direct 
role within the formation of cancer. Recent resequencing of VDR gene identified 194 single-
nucleotide polymorphisms (SNPs). It has been hypothesized that VDR SNPs themselves 
may have a direct impact on formation and prognosis of certain types of cancer, including 
HNSCC. The two most widely investigated receptors regarding their impact and role within 
cancer include a FokI restriction fragment-length polymorphism (RFLP) in exon 2 and an 
adjacent TaqI RFLP in exon 9. These two polymoprhisms were recently investigated with 
respect to their association with HNSCC incidence. Such studies yielded mixed results. 
Findings from one study demonstrated that the heterozygous genotype of Taq I (Tt) 
polymorphism may be associated with an increased susceptibility to HNSCC 20. In a 
separate study, however, both homozygous variant genotypes, TaqI (tt) and FokI (ff), were 
associated with a reduced risk of HNSCC as compared to the more common TaqI (TT) and 
FokI (FF) genotypes. Thus, it remains uncertain as to whether or not specific VDR SPNs 
provide a protective or deleterious effect regarding HNSCC risk 21. However, 
demonstrations of both increased and decreased HNSCC risk warrant continued research 
into how VDR SNPs may not only impact cancer incidence, but also mortality and treatment 
response.  
3.1 Biological plausibility within cancer 
The general biologic characteristics and mechanisms of action detailed above presented two 
main molecular hurdles for scientists considering 1,25(OH)2D3 as a plausible anti-neoplastic 
agent. First, there was the seemingly restricted localization of 1- hydroxylase. The enzyme 
responsible for converting vitamin D into its active form is highly expressed in renal 
proximal tubules and was once thought to be solely expressed intra-renally However, it is 
now known that many non-renal cells, including bone, placenta, prostate, keratinocytes, 
macrophages, T-lymphocytes, dendritic cells and several cancer cells all express the 
converting enzyme capable of producing the hormonally active metabolite 1,25(OH)2D3 22. 
This particular formation of Vitamin D contains a high affinity for the VDR and is capable of 
eliciting an anti-neoplastic response. It is this formation with which we concern ourselves 
for the remainder of the discussion. 
The second major impasse was the restrictive localization of VDR to skeletal tissues. 
However, since VDRs were first discovered their localization has been confirmed on a 
variety of tissues. With respects to SCC, it has been demonstrated that not only do human 
cancer cell lines (SCL-1, SCL-2 ) exhibit VDR expression, but in fact they express the receptor 
in higher amounts than normal human skin cell lines 23. The discovery of extra-renally 
expressed 1- hydroxylase and extra-skeletally expressed VDR was paramount in vitamin 
D’s acceptance as a possible anticancer agent. Such findings sustained the molecular 
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integrity of the theory, paving the way for the initiation of many phase I and phase II clinical 
trials. 
4. Vitamin D and cancer 
Thus far, 1,25(OH)2D3has been presented as a secosteroid whose fundamental intra-nuclear 
action is critical for appropriate regulation of calcium homeostasis and proper bone 
mineralization. Vitamin D, however, has other non-calcemic regulatory functions, including 
many which make it an intriguing anti-neoplastic agent. Four separate cellular functions 
tend to be compromised in order for cancer to thrive within a normal host environment: 1) 
aberrant regulation of differentiation, 2) dysregulated cellular proliferation, 3) newly 
acquired ability permitting invasion and metastasis, 4) dysregulated cell destruction of 
altered self-cells. Numerous published reports have demonstrated that 1,25(OH)2D3 is 
capable of restoring or repairing each of the aforementioned hallmarks of carcinogenesis. It 
does so in a number of ways, including inhibition of cellular proliferation, disruption and 
inhibition of angiogenesis, promoting apoptosis, and improving tumor immunosurveillence.  
4.1 Cellular proliferation and differentiation 
The processes of cellular proliferation and differentiation are intimately intertwined, and the 
aberrant regulation of each is critically important to the prosperity of growing cancer cells. 
The normal cell grows along a continuum of cellular differentiation. As a cell proceeds 
toward terminal differentiation, its ability to divide and proliferate is decreased. This feature 
is exploited and utilized by many newer anti-neoplastic agents, including 1,25(OH)2D3. A 
promising feature of 1,25(OH)2D3 is its ability to manipulate the cell’s state of differentiation. 
In vitro studies in human cell lines demonstrated that 1,25(OH)2D3 is capable of reducing cell 
proliferation by inducing cell cycle arrest in G0/G1 phase while simultaneously promoting 
cellular differentiation 24, 25.  
These results were replicated within murine SCC cell lines which showed that 
administration of 1,25(OH)2D3to cells induces G0/G1 cell-cycle arrest via the transcriptional 
activation of CDKN1B and subsequent dephosphorylation of pRB 26. The study 
demonstrated that in both in vivo and in vitro studies, the increases seen in CDKN1B were 
the result of downregulated p21 activity, a potent CDK inhibitor 26. Human SCC cell lines 
that positively express VDR showed a potent decrease in cellular proliferation when 
exposed to 1,25(OH)2D3 and its analogues 27. Vitamin D’s ability to force cells into 
differentiation may be of critical importance, as such actions can aid in the inhibition of 
tumor cell proliferation 28. 
4.2 Angiogenesis 
Cancer cells will often acquire the ability to escape the confines of the original tumor nidus. 
The tumor cell often relies heavily on its angiogenic properties to spread. In theory, limiting 
the tumor’s ability to aberrantly generate rogue blood supplies may limit its ability to thrive 
and metastasize, offering a potential avenue to achievement of loco-regional control. Several 
studies have demonstrated that 1,25(OH)2D3 contains potent antiangiogenic properties 
capable of reducing the invasiveness of cancer cells. In vitro studies demonstrated that 
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1,25(OH)2D3 and its analogs directly inhibit tumor-derived endothelial cell proliferation in 
addition to disrupting angiogenic signaling in cancer cells 29.  
Within HNSCC cell-lines, treatment with 1,25(OH)2D3 resulted in a significantly lower 
production of pro-angiogenic cytokines, VEGF and PDGF 27. Meanwhile, the pro-
inflammatory and proangiogenic cytokine, IL-8, exhibits no change after administration of 
1,25(OH)2D3 27. The finding of decreasing concentrations of VEGF has prompted 
considerable interest, as it has not only been cited as a marker for tumor metastasis, but also 
used as a prognostic factor in HNSCC patients 30, 31. 
4.3 Apoptosis 
Apart from its actions on the cell cycle, 1,25(OH)2D3 can also suppress cancer growth via 
induction of apoptosis 32-34. Results carried out on human HNSCC cell lines demonstrated 
that exposure to 1,25(OH)2D3 results in the downregulaion of several anti-apoptotic genes. 
In particular, 1,25(OH)2D3 represses the expression of the anti-apoptotic, pro-survival 
gene BCL-2 while simultaneously increasing pro-apoptotic gene products of BAX and 
BAK 35. Studies completed on mouse SCC tumor cells with 1,25(OH)2D3 revealed a form of 
caspase-dependent apoptosis involving the growth-promoting/pro-survival signaling 
molecule, mitogen-activated protein kinase kinase (MEK) 36. The study was able to 
demonstrate that exposure to 1,25(OH)2D3 resulted in increased VDR expression and 
concomitant cleavage of the pro-survival signaling molecule MEK via a caspase-
dependent manner. 
4.4 Immune escape 
Key to the survival of cancer cells is the evasion of destruction, a critically fundamental step 
of which is the ability to evade the immune system. HNSCC, like all cancers, is capable of 
evading the host’s immune system via a number of different mechanisms. Cancer can evade 
antigenic recognition via tissue sequestration, improper lymphocytic homing due to 
improper expression of adhesion molecules, and antigenic shedding and modulation. In 
certain instances, however, antigenic recognition remains intact, despite a poor immune 
response. In such cases, cancers continue to thrive by releasing immunosuppressive 
cytokine, downregulating MHC I complex, or instilling dysregulated or improper 
costimulation 
Numerous studies performed on HNSCC patients have investigated the effects of 
1,25(OH)2D3 on the immune profile of patients. Within the past 10 years, it has been shown 
that not only do monocytes, B-cells, and T-cells express VDR, but also contain the enzyme 1-
-hydroxylase capable of converting 25(OH)D3 into 1,25(OH)2D3 37. Such findings confirmed 
long-standing speculation that vitamin D is critical for the appropriate management and 
integrity of the immune system. Numerous studies have since attempted to understand 
exactly how vitamin D modulates the host immune profile.  
HNSCC itself is associated with profound immunosuppression 38. This is in part due to 
tissue infiltration by immunosuppressive immature progenitor cells with surface marker 
CD34 39, 40. In one study, HNSCC patients treated with 1,25(OH)2D3 exhibited decreased 
levels of intratumoral CD34+ cell populations and diminished the preexisting profound 
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immunoinhibitory effect of the cancer. Such findings suggest that 1,25(OH)2D3 may be 
helpful in overcoming the profound immunosuppression associated with HNSCC 41. 
Tissues of HNSCC patients who received treatment with 1,25(OH)2D3 contained increased 
levels of CD4+ cells and, more significantly, CD8+T cells. Such findings indicate an increased 
infiltration of immune effector cells into the tumor microenvironment. Also prominent was 
an increase in cells expressing the lymphoid activation marker CD69, which represent 
mainly T cells and monocytes. The same study showed that HNSCC patients who received 
1,25(OH)2D3 prior to treatment had a lengthier time to tumor recurrence compared with 
patients who were not treated before surgery. The treatment arm exhibited a median time to 
recurrence that was almost 3.5-fold longer than control patients who were untreated before 
surgery 42. These findings are complemented by separate studies suggesting that treatment 
with 1,25(OH)2D3 may be an appropriate method of restarting the immune system 43. 
5. Future clinical considerations 
One of the most discussed aspects regarding the implementation of vitamin D as an anti-
cancer medication is dosing regimen. The Institute of Medicine recently addressed vitamin 
D dosing regimens in its newly published Dietary Referenced Intakes for Vitamin D. Their 
review of the literature yielded the suggested dietary intake of 600 IU per day for persons 1 
to 70 years of age and 800 IU per day for persons over 70. Such intakes corresponded to 
serum 25(OH)D levels of at least 20 ng per milliliter (50 nmol per liter) with recommended 
daily ingestion not to exceed 4000 IU per day 44. The same review concluded that the 
prevalence of vitamin D deficiency in North America, which previously published reports 
had suggested to be as high as 54% in some populations, has been drastically overestimated 
45. The authors concluded that the vast majority of North American individuals have serum 
25(OH)D concentrations above 20 ng per milliliter, which is adequate for bone health in at 
least 97.5% of the population 
Another area of debate is the concept of vitamin D screening as a predictor for cancer 
incidence. Since its inception, many have taken disagreed with such practices. One of the 
main areas of contention rests in the number of confounding variables associated with low 
serum 25(OH)D levels. These variables, which include obesity, lack of physical activity, and 
poor diet or supplementation practices, have the ability to impact cancer risk. Critics also 
cite reverse-causation bias, noting that in certain individuals poor health reduces one’s 
ability to participate in outdoor activities, resulting in lower vitamin D levels. 
6. Conclusion and future perspective 
It is the opinion of the authors that the role of 1,25(OH)2D3 as an anti-cancer agent warrants 
continued clinical and laboratory exploration. Further investigation into the relationship 
calls for randomized control trials of vitamin D for cancer prevention. As noted by the 
recently published IRAC review, observational studies themselves are unlikely to 
“disentangle the complex relationships between vitamin D and known cancer risk factors 
46.” Such reports, however, have paved the way for numerous ongoing phase I and II clinical 
trials which should begin to elucidate what role, if any, 1,25(OH)2D3 may play in the 
treatment of HNSCC. 
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